IPO to ICI
12 March 2007

The US drugs group is paying E11bn for Organon Biosciences that’s well above what Azko’s pharma unit was expected to fetch in an IPO. The deal just about stacks up financially for Schering. Meanwhile Akzo now has the firepower to bid for ICI.